Cascade Investment Advisors Inc. Buys 2,425 Shares of Pfizer Inc. (NYSE:PFE)

Cascade Investment Advisors Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 4.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 58,959 shares of the biopharmaceutical company’s stock after purchasing an additional 2,425 shares during the quarter. Cascade Investment Advisors Inc.’s holdings in Pfizer were worth $1,636,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Greylin Investment Management Inc lifted its position in Pfizer by 43.9% in the first quarter. Greylin Investment Management Inc now owns 249,672 shares of the biopharmaceutical company’s stock valued at $6,928,000 after purchasing an additional 76,137 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in Pfizer by 7.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,701,161 shares of the biopharmaceutical company’s stock valued at $47,207,000 after purchasing an additional 111,509 shares during the last quarter. Krilogy Financial LLC raised its holdings in shares of Pfizer by 5.6% during the first quarter. Krilogy Financial LLC now owns 25,191 shares of the biopharmaceutical company’s stock valued at $699,000 after acquiring an additional 1,343 shares in the last quarter. Beddow Capital Management Inc. raised its holdings in shares of Pfizer by 22.5% during the first quarter. Beddow Capital Management Inc. now owns 153,885 shares of the biopharmaceutical company’s stock valued at $4,270,000 after acquiring an additional 28,224 shares in the last quarter. Finally, Patton Albertson Miller Group LLC raised its holdings in shares of Pfizer by 22.1% during the first quarter. Patton Albertson Miller Group LLC now owns 127,228 shares of the biopharmaceutical company’s stock valued at $3,531,000 after acquiring an additional 23,035 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 3.0 %

Shares of NYSE PFE traded down $0.90 during trading on Thursday, reaching $28.70. The company had a trading volume of 41,998,922 shares, compared to its average volume of 42,563,102. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The stock has a market cap of $162.63 billion, a PE ratio of -478.25, a P/E/G ratio of 1.11 and a beta of 0.63. The business’s 50-day moving average is $27.26 and its 200 day moving average is $27.98. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the prior year, the firm posted $1.23 earnings per share. The company’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 5.85%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Morgan Stanley upped their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.